Risk of using hydroxychloroquine as a treatment of COVID-19.

Link to article at PubMed

Related Articles

Risk of using hydroxychloroquine as a treatment of COVID-19.

Int J Risk Saf Med. 2020 May 27;:

Authors: Alanagreh L, Alzoughool F, Atoum M

The emerging COVID-19 pandemic poses a threat to the global health care system. Given the lack of antiviral therapies or vaccines for the disease, the antimalarial drug hydroxychloroquine (HCQ) obtained much attention as a treatment for COVID-19. However, there are limited and uncertain clinical data to support the beneficial effect of this drug in COVID-19 treatment. HCQ has several side effects and warnings, including blindness, heart failure, and renal toxicity, even with recommended doses. For severe cases of COVID-19 or in patients with preexisting conditions, administering such a drug could be fatal, particularly when taken at high doses or in combination with other antibiotics. However, further well-designed studies that would address the optimal dose, duration of treatment, possible side effects, and long-term usage outcomes are needed to make the final decision. In this paper, we aim to discuss the risk of using HCQ in treating COVID-19 patients, including its possible side effects.

PMID: 32474476 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *